New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth

PURPOSE: Combining molecular therapies with chemotherapy may offer an improved clinical outcome for chemoresistant tumours. Sphingosine-1-phosphate (S1P) receptor antagonist and sphingosine kinase 1 (SK1) inhibitor FTY720 (FTY) has promising anticancer properties, however, it causes systemic lymphop...

Descripción completa

Detalles Bibliográficos
Autores principales: Alshaker, Heba, Wang, Qi, Srivats, Shyam, Chao, Yimin, Cooper, Colin, Pchejetski, Dmitri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Preclinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602005/
https://www.ncbi.nlm.nih.gov/pubmed/28695300
http://dx.doi.org/10.1007/s10549-017-4380-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602005/
https://www.ncbi.nlm.nih.gov/pubmed/28695300
http://dx.doi.org/10.1007/s10549-017-4380-8

Ejemplares similares